Characterizing autism spectrum disorders by key biochemical pathways

Frontiers in Neuroscience

Volumn 9, Issue SEP, 2015, Pages

  Subramanian, Megha ^a   Timmerman, Christina K ^a   Schwartz, Joshua L ^a   Pham, Daniel L ^a   Meffert, Mollie K ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autism spectrum disorders (ASD); ERK signaling; MAP kinase signaling system; MTOR pathway; Neurotrophic factors; Protein synthesis

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CILIARY NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; INITIATION FACTOR 4E BINDING PROTEIN; INITIATION FACTOR 4E BINDING PROTEIN 2; METHYL CPG BINDING PROTEIN 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEUROTROPHIN 3; NEUROTROPHIN 4; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE A; PROTEIN TYROSINE KINASE C; SOMATOMEDIN C; UNCLASSIFIED DRUG; VASCULOTROPIN;

5' UNTRANSLATED REGION; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; AUTISM; AUTS2 GENE; BRAIN SIZE; CELL POPULATION; CELL PROLIFERATION; CHD8 GENE; CHROMOSOME 22Q; CONNECTOME; COPY NUMBER VARIATION; DENDRITIC SPINE; DEPRESSION; DGCR8 GENE; DISEASE ASSOCIATION; DOWN REGULATION; DYRK1A GENE; ENZYME ACTIVATION; ENZYME INHIBITION; FMR1 GENE; FRAGILE X SYNDROME; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GAIN OF FUNCTION MUTATION; GENE; GENE DELETION; GENE DUPLICATION; GENE EXPRESSION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GROWTH REGULATION; HEAD CIRCUMFERENCE; HUMAN; HUNTINGTON CHOREA; IN VIVO STUDY; INCIDENCE; INTELLECTUAL IMPAIRMENT; LOSS OF FUNCTION MUTATION; MACROCEPHALY; MECP2 GENE; MICROCEPHALY; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PHENOTYPE; POSTNATAL DEVELOPMENT; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; RESTING STATE NETWORK; RETT SYNDROME; REVIEW; RTN4R GENE; SIGNAL TRANSDUCTION; SUBSTANCE ABUSE; TBX1 GENE; TUBEROUS SCLEROSIS; ZDHHC8 GENE;

EID: 84946549812     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2015.00313     Document Type: Review

References (211)

1. Abrahams, B. S., and Geschwind, D. H. (2008). Advances in autism genetics: on the threshold of a new neurobiology. Nat. Rev. Genet. 9, 341-355. doi: 10.1038/nrg2346
2. Amir, R. E., Van den Veyver, I. B., Wan, M., Tran, C. Q., Francke, U., and Zoghbi, H. Y. (1999). Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 23, 185-188. doi: 10.1038/13810
3. Amiri, A., Cho, W., Zhou, J., Birnbaum, S. G., Sinton, C. M., McKay, R. M., et al. (2012). Pten deletion in adult hippocampal neural stem/progenitor cells causes cellular abnormalities and alters neurogenesis. J. Neurosci. 32, 5880-5890. doi: 10.1523/JNEUROSCI.5462-11.2012
4. Anderson, J. S. (2014). "Cortical underconnectivity hypothesis in autism: evidence from functional connectivity MRI," in Comprehensive Guide to Autism, eds V. B. Patel, V. R. Preedy, and C. R. Martin (New York, NY: Springer Science+Business Media), 1457-1471. doi: 10.1007/978-1-4614-4788-7_81
5. Anderson, J. S., Druzgal, T. J., Froehlich, A., Dubray, M. B., Lange, N., Alexander, A. L., et al. (2011). Decreased interhemispheric functional connectivity in autism. Cereb. Cortex 21, 1134-1146. doi: 10.1093/cercor/bhq190
6. Antion, M. D., Hou, L., Wong, H., Hoeffer, C. A., and Klann, E. (2008). mGluR-dependent long-term depression is associated with increased phosphorylation of S6 and synthesis of elongation factor 1A but remains expressed in S6K-deficient mice. Mol. Cell. Biol. 28, 2996-3007. doi: 10.1128/MCB.00201-08
7. Assaf, M., Jagannathan, K., Calhoun, V. D., Miller, L., Stevens, M. C., Sahl, R., et al. (2010). Abnormal functional connectivity of default mode sub-networks in autism spectrum disorder patients. Neuroimage 53, 247-256. doi: 10.1016/j.neuroimage.2010.05.067
8. Auerbach, B. D., Osterweil, E. K., and Bear, M. F. (2011). Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature 480, 63-68. doi: 10.1038/nature10658
9. Backman, S. A., Stambolic, V., Suzuki, A., Haight, J., Elia, A., Pretorius, J., et al. (2001). Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease. Nat. Genet. 29, 396-403. doi: 10.1038/ng782
10. Baj, G., Patrizio, A., Montalbano, A., Sciancalepore, M., and Tongiorgi, E. (2014). Developmental and maintenance defects in Rett syndrome neurons identified by a new mouse staging system in vitro. Front. Cell. Neurosci. 8:18. doi: 10.3389/fncel.2014.00018
11. Bakkaloglu, B., O'Roak, B. J., Louvi, A., Gupta, A. R., Abelson, J. F., Morgan, T. M., et al. (2008). Molecular cytogenetic analysis and resequencing of contactin associated protein-like 2 in autism spectrum disorders. Am. J. Hum. Genet. 82, 165-173. doi: 10.1016/j.ajhg.2007.09.017
12. Banko, J. L., Hou, L., Poulin, F., Sonenberg, N., and Klann, E. (2006). Regulation of eukaryotic initiation factor 4E by converging signaling pathways during metabotropic glutamate receptor-dependent long-term depression. J. Neurosci. 26, 2167-2173. doi: 10.1523/JNEUROSCI.5196-05.2006
13. Banko, J. L., Poulin, F., Hou, L., DeMaria, C. T., Sonenberg, N., and Klann, E. (2005). The translation repressor 4E-BP2 is critical for eIF4F complex formation, synaptic plasticity, and memory in the hippocampus. J. Neurosci. 25, 9581-9590. doi: 10.1523/JNEUROSCI.2423-05.2005
14. Bartholomeusz, H. H., Courchesne, E., and Karns, C. M. (2002). Relationship between head circumference and brain volume in healthy normal toddlers, children, and adults. Neuropediatrics 33, 239-241. doi: 10.1055/s-2002-36735
15. Bateup, H. S., Johnson, C. A., Denefrio, C. L., Saulnier, J. L., Kornacker, K., and Sabatini, B. L. (2013). Excitatory/Inhibitory synaptic imbalance leads to hippocampal hyperexcitability in mouse models of tuberous sclerosis. Neuron 78, 510-522. doi: 10.1016/j.neuron.2013.03.017
16. Ben-David, E., Granot-Hershkovitz, E., Monderer-Rothkoff, G., Lerer, E., Levi, S., Yaari, M., et al. (2011). Identification of a functional rare variant in autism using genome-wide screen for monoallelic expression. Hum. Mol. Genet. 20, 3632-3641. doi: 10.1093/hmg/ddr283
17. Bernier, R., Golzio, C., Xiong, B., Stessman, H. A., Coe, B. P., Penn, O., et al. (2014). Disruptive CHD8 mutations define a subtype of autism early in development. Cell 158, 263-276. doi: 10.1016/j.cell.2014.06.017
18. Beunders, G., Voorhoeve, E., Golzio, C., Pardo, L. M., Rosenfeld, J. A., Talkowski, M. E., et al. (2013). Exonic deletions in AUTS2 cause a syndromic form of intellectual disability and suggest a critical role for the C terminus. Am. J. Hum. Genet. 92, 210-220. doi: 10.1016/j.ajhg.2012.12.011
19. Bhakar, A. L., Dölen, G., and Bear, M. F. (2012). The pathophysiology of fragile X (and what it teaches us about synapses). Annu. Rev. Neurosci. 35, 417-443. doi: 10.1146/annurev-neuro-060909-153138
20. Bhattacharya, A., Kaphzan, H., Alvarez-Dieppa, A. C., Murphy, J. P., Pierre, P., and Klann, E. (2012). Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice. Neuron 76, 325-337. doi: 10.1016/j.neuron.2012.07.022
21. Bilousova, T. V., Dansie, L., Ngo, M., Aye, J., Charles, J. R., Ethell, D. W., et al. (2009). Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J. Med. Genet. 46, 94-102. doi: 10.1136/jmg.2008.061796
22. Borrie, S. C., Baeumer, B. E., and Bandtlow, C. E. (2012). The Nogo-66 receptor family in the intact and diseased CNS. Cell Tissue Res. 349, 105-117. doi: 10.1007/s00441-012-1332-9
23. Bronicki, L. M., Redin, C., Drunat, S., Piton, A., Lyons, M., Passemard, S., et al. (2015). Ten new cases further delineate the syndromic intellectual disability phenotype caused by mutations in DYRK1A. Eur. J. Hum. Genet. doi: 10.1038/ejhg.2015.29. [Epub ahead of print]
24. Butler, M. G., Dasouki, M. J., Zhou, X.-P., Talebizadeh, Z., Brown, M., Takahashi, T. N., et al. (2005). Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J. Med. Genet. 42, 318-321. doi: 10.1136/jmg.2004.024646
25. Byts, N., Samoylenko, A., Woldt, H., Ehrenreich, H., and Sirén, A. L. (2006). Cell type specific signalling by hematopoietic growth factors in neural cells. Neurochem. Res. 31, 1219-1230. doi: 10.1007/s11064-006-9149-0
26. Çaku, A., Pellerin, D., Bouvier, P., Riou, E., and Corbin, F. (2014). Effect of lovastatin on behavior in children and adults with fragile X syndrome: an open-label study. Am. J. Med. Genet. A, 164, 2834-2842. doi: 10.1002/ajmg.a.36750
27. Callan, M. A., Cabernard, C., Heck, J., Luois, S., Doe, C. Q., and Zarnescu, D. C. (2010). Fragile X protein controls neural stem cell proliferation in the Drosophila brain. Hum. Mol. Genet. 19, 3068-3079. doi: 10.1093/hmg/ddq213
28. Castrén, M., and Castrén, E. (2014). BDNF in fragile X syndrome. Neuropharmacology 76 Pt C, 729-736. doi: 10.1016/j.neuropharm.2013.05.018
29. Castrén, M., Tervonen, T., Kärkkäinen, V., Heinonen, S., Castrén, E., Larsson, K., et al. (2005). Altered differentiation of neural stem cells in fragile X syndrome. Proc. Natl. Acad. Sci. U.S.A. 102, 17834-19839. doi: 10.1073/pnas.0508995102
30. Castro, J., Garcia, R. I., Kwok, S., Banerjee, A., Petravicz, J., Woodson, J., et al. (2014). Functional recovery with recombinant human IGF1 treatment in a mouse model of Rett Syndrome. Proc. Natl. Acad. Sci. U.S.A. 111, 9941-9946. doi: 10.1073/pnas.1311685111
31. Chahrour, M., and Zoghbi, H. Y. (2007). The story of rett syndrome: from clinic to neurobiology. Neuron 56, 422-437. doi: 10.1016/j.neuron.2007.10.001
32. Chalhoub, N., and Baker, S. J. (2009). PTEN and the PI3-kinase pathway in cancer. Annu. Rev. Pathol. 4, 127-150. doi: 10.1146/annurev.pathol.4.110807.092311
33. Chalhoub, N., Kozma, S. C., and Baker, S. J. (2006). S6k1 is not required for Pten-deficient neuronal hypertrophy. Brain Res. 1100, 32-41. doi: 10.1016/j.brainres.2006.05.013
34. Chang, Q., Khare, G., Dani, V., Nelson, S., and Jaenisch, R. (2006). The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. Neuron 49, 341-348. doi: 10.1016/j.neuron.2005.12.027
35. Chao, H. T., Zoghbi, H. Y., and Rosenmund, C. (2007). MeCP2 controls excitatory synaptic strength by regulating glutamatergic synapse number. Neuron 56, 58-65. doi: 10.1016/j.neuron.2007.08.018
36. Chao, M. V., Rajagopal, R., and Lee, F. S. (2006). Neurotrophin signalling in health and disease. Clin. Scie. (Lond.) 110, 167-173. doi: 10.1042/CS20050163
37. Chapleau, C. A., and Pozzo-Miller, L. (2012). Divergent roles of p75 NTR and Trk receptors in BDNF's effects on dendritic spine density and morphology. Neural Plast. 2012:578057. doi: 10.1155/2012/578057
38. Chen, W. G., Chang, Q., Lin, Y., Meissner, A., West, A. E., Griffith, E. C., et al. (2003). Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science 302, 885-889. doi: 10.1126/science.1086446
39. Chen, Y. H., Liao, D. L., Lai, C. H., and Chen, C. H. (2013). Genetic analysis of AUTS2 as a susceptibility gene of heroin dependence. Drug Alcohol Depend. 128, 238-242. doi: 10.1016/j.drugalcdep.2012.08.029
40. Cheng, T.-L., and Qiu, Z. (2014). MeCP2: multifaceted roles in gene regulation and neural development. Neurosci. Bull. 30, 601-609. doi: 10.1007/s12264-014-1452-6
41. Cheng, T. L., Wang, Z., Liao, Q., Zhu, Y., Zhou, W. H., Xu, W., et al. (2014). MeCP2 Suppresses nuclear microRNA processing and dendritic growth by regulating the DGCR8/Drosha complex. Dev. Cell 28, 547-560. doi: 10.1016/j.devcel.2014.01.032
42. Chévere-Torres, I., Kaphzan, H., Bhattacharya, A., Kang, A., Maki, J. M., Gambello, M. J., et al. (2012). Metabotropic glutamate receptor-dependent long-term depression is impaired due to elevated ERK signaling in the DeltaRG mouse model of tuberous sclerosis complex. Neurobiol. Dis. 45, 1101-1110. doi: 10.1016/j.nbd.2011.12.028
43. Choi, Y.-J., Di Nardo, A., Kramvis, I., Meikle, L., Kwiatkowski, D. J., Sahin, M., et al. (2008). Tuberous sclerosis complex proteins control axon formation. Genes Dev. 22, 2485-2495. doi: 10.1101/gad.1685008
44. Chudley, A., and Hagerman, R. (1987). Fragile X syndrome. J. Petriatrics 110, 821-831. doi: 10.1016/s0022-3476(87)80392-x
45. Clipperton-Allen, A. E., and Page, D. T. (2014). Pten haploinsufficient mice show broad brain overgrowth but selective impairments in autism-relevant behavioral tests. Hum. Mol. Genet. 23, 3490-3505. doi: 10.1093/hmg/ddu057
46. Cloëtta, D., Thomanetz, V., Baranek, C., Lustenberger, R. M., Lin, S., Oliveri, F., et al. (2013). Inactivation of mTORC1 in the developing brain causes microcephaly and affects gliogenesis. J. Neurosci. 33, 7799-7810. doi: 10.1523/JNEUROSCI.3294-12.2013
47. Collins, A. L., Levenson, J. M., Vilaythong, A. P., Richman, R., Armstrong, D. L., Noebels, J. L., et al. (2004). Mild overexpression of MeCP2 causes a progressive neurological disorder in mice. Hum. Mol. Genet. 13, 2679-2689. doi: 10.1093/hmg/ddh282
48. Courchesne, E., Carper, R., and Akshoomoff, N. (2003). Evidence of brain overgrowth in the first year of life in autism. J. Am. Med. Assoc. 290, 337-344. doi: 10.1001/jama.290.3.337
49. Courchesne, E., Pierce, K., Schumann, C. M., Redcay, E., Buckwalter, J. A., Kennedy, D. P., et al. (2007). Mapping early brain development in autism. Neuron, 56, 399-413. doi: 10.1016/j.neuron.2007.10.016
50. Cruz-Martín, A., Crespo, M., and Portera-Cailliau, C. (2010). Delayed stabilization of dendritic spines in fragile X mice. J. Neurosci. 30, 7793-7803. doi: 10.1523/JNEUROSCI.0577-10.2010
51. Curatolo, P., Bombardieri, R., and Jozwiak, S. (2008). Tuberous sclerosis. Lancet 372, 657-668. doi: 10.1016/S0140-6736(08)61279-9
52. Dani, V. S., Chang, Q., Maffei, A., Turrigiano, G. G., Jaenisch, R., and Nelson, S. B. (2005). Reduced cortical activity due to a shift in the balance between excitation and inhibition in a mouse model of Rett syndrome. Proc. Natl. Acad. Sci. U.S.A. 102, 12560-12565. doi: 10.1073/pnas.0506071102
53. Darnell, J. C., Van Driesche, S. J., Zhang, C., Hung, K. Y. S., Mele, A., Fraser, C. E., et al. (2011). FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 146, 247-261. doi: 10.1016/j.cell.2011.06.013
54. Dawbarn, D., and Allen, S. J. (2003). Neurotrophins and neurodegeneration. Neuropathol. Appl. Neurobiol. 29, 211-230. doi: 10.1046/j.1365-2990.2003.00487.x
55. De Rubeis, S., He, X., Goldberg, A. P., Poultney, C. S., Samocha, K., Ercument Cicek, A., et al. (2014). Synaptic, transcriptional and chromatin genes disrupted in autism. Nature 515, 209-215. doi: 10.1038/nature13772
56. Dölen, G., Osterweil, E., Rao, B. S., Smith, G. B., Auerbach, B. D., Chattarji, S., et al. (2007). Correction of fragile X syndrome in mice. Neuron, 56, 955-962. doi: 10.1016/j.neuron.2007.12.001
57. Drew, L. J., Crabtree, G. W., Markx, S., Stark, K. L., Chaverneff, F., Xu, B., et al. (2011a). The 22q11.2 microdeletion: Fifteen years of insights into the genetic and neural complexity of psychiatric disorders. Int. J. Dev. Neurosci. 29, 259-281. doi: 10.1016/j.ijdevneu.2010.09.007
58. Drew, L. J., Stark, K. L., Fénelon, K., Karayiorgou, M., Macdermott, A. B., and Gogos, J. A. (2011b). Evidence for altered hippocampal function in a mouse model of the human 22q11.2 microdeletion. Mol. Cell. Neurosci. 47, 293-305. doi: 10.1016/j.mcn.2011.05.008
59. Dziembowska, M., Pretto, D. I., Janusz, A., Kaczmarek, L., Leigh, M. J., Gabriel, N., et al. (2013). High MMP-9 activity levels in fragile X syndrome are lowered by minocycline. Am. J. Med. Genet. A, 161, 1897-1903. doi: 10.1002/ajmg.a.36023
60. Eapen, V., and Clarke, R. A. (2014). Autism spectrum disorders: from genotypes to phenotypes. Front. Hum. Neurosci. 8:914. doi: 10.3389/fnhum.2014.00914
61. Ehninger, D., Han, S., Shilyansky, C., Zhou, Y., Li, W., Kwiatkowski, D. J., et al. (2008). Reversal of learning deficits in a Tsc2+/-mouse model of tuberous sclerosis. Nat. Med. 14, 843-848. doi: 10.1038/nm1788
62. Elia, J., Gai, X., Xie, H. M., Perin, J. C., Geiger, E., Glessner, J. T., et al. (2010). Rare structural variants found in attention-deficit hyperactivity disorder are preferentially associated with neurodevelopmental genes. Mol. Psychiatry 15, 637-646. doi: 10.1038/mp.2009.57
63. Ellegood, J., Anagnostou, E., Babineau, B. A., Crawley, J. N., Lin, L., Genestine, M., et al. (2015). Clustering autism: using neuroanatomical differences in 26 mouse models to gain insight into the heterogeneity. Mol. Psychiatry 20, 118-125. doi: 10.1038/mp.2014.98
64. Ellegood, J., Markx, S., Lerch, J. P., Steadman, P. E., Genç, C., Provenzano, F., et al. (2014). Neuroanatomical phenotypes in a mouse model of the 22q11.2 microdeletion. Mol. Psychiatry 19, 99-107. doi: 10.1038/mp.2013.112
65. Faridar, A., Jones-davis, D., Rider, E., Li, J., Gobius, I., Morcom, L., et al. (2014). Mapk/Erk activation in an animal model of social deficits shows a possible link to Autism. Mol. Autism 5:57. doi: 10.1186/2040-2392-5-57
66. Ferrara, N., Gerber, H. P., and LeCouter, J. (2003). The biology of VEGF and its receptors. Nat. Med. 9, 669-676. doi: 10.1038/nm0603-669
67. Fombonne, E., Rogé, B., Claverie, J., Courty, S., and Frémolle, J. (1999). Microcephaly and macrocephaly in autism. J. Autism Dev. Disord. 29, 113-119. doi: 10.1023/A:1023036509476
68. Fraser, M. M., Bayazitov, I. T., Zakharenko, S. S., and Baker, S. J. (2008). Phosphatase and tensin homolog, deleted on chromosome 10 deficiency in brain causes defects in synaptic structure, transmission and plasticity, and myelination abnormalities. Neuroscience 151, 476-488. doi: 10.1016/j.neuroscience.2007.10.048
69. Gadow, K. D., Roohi, J., Devincent, C. J., Kirsch, S., and Hatchwell, E. (2009). Association of COMT (Val158Met) and BDNF (Val66Met) gene polymorphisms with anxiety, ADHD and tics in children with autism spectrum disorder. J. Autism Dev. Disord. 39, 1542-1551. doi: 10.1007/s10803-009-0794-4
70. Gao, Z., Lee, P., Stafford, J. M., von Schimmelmann, M., Schaefer, A., and Reinberg, D. (2014). An AUTS2-Polycomb complex activates gene expression in the CNS. Nature 516, 349-354. doi: 10.1038/nature13921
71. Gasparini, L., and Xu, H. (2003). Potential roles of insulin and IGF-1 in Alzheimer's disease. Trends Neurosci. 26, 404-406. doi: 10.1016/S0166-2236(03)00163-2
72. Gibson, J. R., Bartley, A. F., Hays, S. A., and Huber, K. M. (2008). Imbalance of neocortical excitation and inhibition and altered UP states reflect network hyperexcitability in the mouse model of fragile X syndrome. J. Neurophysiol. 100, 2615-2626. doi: 10.1152/jn.90752.2008
73. Gilman, S. R., Iossifov, I., Levy, D., Ronemus, M., Wigler, M., and Vitkup, D. (2011). Rare De novo variants associated with autism implicate a large functional network of genes involved in formation and function of synapses. Neuron 70, 898-907. doi: 10.1016/j.neuron.2011.05.021
74. Gkogkas, C. G., Khoutorsky, A., Cao, R., Jafarnejad, S. M., Prager-Khoutorsky, M., Giannakas, N., et al. (2014). Pharmacogenetic inhibition of eIF4E-Dependent Mmp9 mRNA translation reverses Fragile X syndrome-like phenotypes. Cell Rep. 9, 1742-1755. doi: 10.1016/j.celrep.2014.10.064
75. Gkogkas, C. G., Khoutorsky, A., Ran, I., Rampakakis, E., Nevarko, T., Weatherill, D. B., et al. (2013). Autism-related deficits via dysregulated eIF4E-dependent translational control. Nature 493, 371-377. doi: 10.1038/nature11628
76. Glessner, J. T., Wang, K., Cai, G., Korvatska, O., Kim, C. E., Wood, S., et al. (2009a). Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature 459, 569-573. doi: 10.1038/nature07953
77. Glessner, J. T., Wang, K., Cai, G., Korvatska, O., Kim, C. E., Wood, S., et al. (2009b). Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature 459, 569-573. doi: 10.1038/nature07953
78. Goldin, M., and Segal, M. (2003). Protein kinase C and ERK involvement in dendritic spine plasticity in cultured rodent hippocampal neurons. Eur. J. Neurosci. 17, 2529-2539. doi: 10.1046/j.1460-9568.2003.02694.x
79. Gonçalves, J. T., Anstey, J. E., Golshani, P., and Portera-Cailliau, C. (2013). Circuit level defects in the developing neocortex of Fragile X mice. Nat. Neurosci. 16, 903-909. doi: 10.1038/nn.3415
80. Goorden, S. M. I., Van Woerden, G. M., Van Der Weerd, L., Cheadle, J. P., and Elgersma, Y. (2007). Cognitive deficits in Tsc1+/-mice in the absence of cerebral lesions and seizures. Ann. Neurol. 62, 648-655. doi: 10.1002/ana.21317
81. Govindarajan, B., Mizesko, M. C., Miller, M. S., Onda, H., Nunnelly, M., Casper, K., et al. (2003). Tuberous sclerosis-associated neoplasms express activated p42/44 mitogen-activated protein (MAP) kinase, and inhibition of MAP kinase signaling results in decreased in vivo tumor growth. Clin. Cancer Res. 9, 3469-3475. Available online at: clincancerres.aacrjournals.org/content/9/9/3469.long
82. Greer, J. M., and Wynshaw-Boris, A. (2006). Pten and the brain: sizing up social interaction. Neuron 50, 343-345. doi: 10.1016/j.neuron.2006.04.021
83. Gross, C., Raj, N., Molinaro, G., Allen, A. G., Whyte, A. J., Gibson, J. R., et al. (2015). Selective role of the catalytic PI3K subunit p110ß in impaired higher order cognition in Fragile X syndrome. Cell Rep. 11, 681-688. doi: 10.1016/j.celrep.2015.03.065
84. Guertin, D. A., Stevens, D. M., Thoreen, C. C., Burds, A. A., Kalaany, N. Y., Moffat, J., et al. (2006). Ablation in Mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKC, but not S6K1. Dev. Cell 11, 859-871. doi: 10.1016/j.devcel.2006.10.007
85. Guy, J., Hendrich, B., Holmes, M., Martin, J. E., and Bird, A. (2001). A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat. Genet. 27, 322-326. doi: 10.1038/85899
86. Han, J., Lee, Y., Yeom, K. H., Nam, J. W., Heo, I., Rhee, J. K., et al. (2006). Molecular basis for the recognition of primary microRNAs by the Drosha-DGCR8 complex. Cell 125, 887-901. doi: 10.1016/j.cell.2006.03.043
87. Harlow, E. G., Till, S. M., Russell, T. A., Wijetunge, L. S., Kind, P., and Contractor, A. (2010). Critical period plasticity is disrupted in the barrel cortex of Fmr1 knockout mice. Neuron 65, 385-398. doi: 10.1016/j.neuron.2010.01.024
88. Hay, N. (2005). The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8, 179-183. doi: 10.1016/j.ccr.2005.08.008
89. He, C. X., and Portera-Cailliau, C. (2013). The trouble with spines in fragile X syndrome: density, maturity and plasticity. Neuroscience 251, 120-128. doi: 10.1016/j.neuroscience.2012.03.049
90. He, Q., Nomura, T., Xu, J., and Contractor, A. (2014). The developmental switch in GABA polarity is delayed in fragile X mice. J. Neurosci. 34, 446-450. doi: 10.1523/JNEUROSCI.4447-13.2014
91. Hefti, F. (1994). Neurotrophic factor therapy for nervous system degenerative diseases. J. Neurobiol. 25, 1418-1435. doi: 10.1002/neu.480251109
92. Herbert, K. M., Pimienta, G., DeGregorio, S. J., Alexandrov, A., and Steitz, J. A. (2013). Phosphorylation of DGCR8 increases its intracellular stability and induces a progrowth miRNA Profile. Cell Rep. 5, 1070-1081. doi: 10.1016/j.celrep.2013.10.017
93. Hoeffer, C. A., Sanchez, E., Hagerman, R. J., Mu, Y., Nguyen, D. V., Wong, H., et al. (2012). Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome. Genes Brain Behav. 11, 332-341. doi: 10.1111/j.1601-183X.2012.00768.x
94. Horev, G., Ellegood, J., Lerch, J. P., Son, Y.-E. E., Muthuswamy, L., Vogel, H., et al. (2011). Dosage-dependent phenotypes in models of 16p11.2 lesions found in autism. Proc. Natl. Acad. Sci. U.S.A. 108, 17076-17081. doi: 10.1073/pnas.1114042108
95. Hori, K., Nagai, T., Shan, W., Sakamoto, A., Taya, S., Hashimoto, R., et al. (2014). Cytoskeletal regulation by AUTS2 in neuronal migration and neuritogenesis. Cell Rep. 9, 2166-2179. doi: 10.1016/j.celrep.2014.11.045
96. Hsieh, H.-L., Wang, H.-H., Wu, W.-B., Chu, P.-J., and Yang, C.-M. (2010). Transforming growth factor-ß1 induces matrix metalloproteinase-9 and cell migration in astrocytes: roles of ROS-dependent ERK-and JNK-NF-κB pathways. J. Neuroinflammation 7, 88. doi: 10.1186/1742-2094-7-88
97. Irwin, S. A., Patel, B., Idupulapati, M., Harris, J. B., Crisostomo, R. A., Larsen, B. P., et al. (2001). Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile-X syndrome: a quantitative examination. Am. J. Med. Genet. 98, 161-167. doi: 10.1002/1096-8628(20010115)98:2<161::AID-AJMG1025>3.0.CO;2-B
98. Jacquemont, S., Reymond, A., Zufferey, F., Harewood, L., Walters, R. G., Kutalik, Z., et al. (2011). Mirror extreme BMI phenotypes associated with gene dosage at the chromosome 16p11.2 locus. Nature 478, 97-102. doi: 10.1038/nature10406
99. Jaworski, J., Spangler, S., Seeburg, D. P., Hoogenraad, C. C., and Sheng, M. (2005). Control of dendritic arborization by the phosphoinositide-3'-kinase-Akt-mammalian target of rapamycin pathway. J. Neurosci. 25, 11300-11312. doi: 10.1523/JNEUROSCI.2270-05.2005
100. Je, H. S., Yang, F., Ji, Y., Nagappan, G., Hempstead, B. L., and Lu, B. (2012). Role of pro-brain-derived neurotrophic factor (proBDNF) to mature BDNF conversion in activity-dependent competition at developing neuromuscular synapses. Proc. Natl. Acad. Sci. U.S.A. 109, 15924-15929. doi: 10.1073/pnas.1207767109
101. Jellinger, K. A. (2003). Rett syndrome-an update: review. J. Neural Transm. 110, 681-701. doi: 10.1007/s00702-003-0822-z
102. Jeste, S. S., Sahin, M., Bolton, P., Ploubidis, G. B., and Humphrey, A. (2008). Characterization of autism in young children with tuberous sclerosis complex. J. Child Neurol. 23, 520-525. doi: 10.1177/0883073807309788
103. Junger, H., and Junger, W. G. (1998). CNTF and GDNF, but not NT-4, support corticospinal motor neuron growth via direct mechanisms. Neuroreport 9, 3749-3754. doi: 10.1097/00001756-199811160-00033
104. Ka, M., Condorelli, G., Woodgett, J. R., and Kim, W.-Y. (2014). mTOR regulates brain morphogenesis by mediating GSK3 signaling. Development 141, 4076-4086. doi: 10.1242/dev.108282
105. Kalscheuer, V. M., FitzPatrick, D., Tommerup, N., Bugge, M., Niebuhr, E., Neumann, L. M., et al. (2007). Mutations in autism susceptibility candidate 2 (AUTS2) in patients with mental retardation. Hum. Genet. 121, 501-509. doi: 10.1007/s00439-006-0284-0
106. Karayiorgou, M., Simon, T. J., and Gogos, J. A. (2010). 22q11.2 microdeletions: linking DNA structural variation to brain dysfunction and schizophrenia. Nature Rev. Neurosci. 11, 402-416. doi: 10.1038/nrn2841
107. Kates, W. R., Abrams, M. T., Kaufmann, W. E., Breiter, S. N., and Reiss, A. L. (1997). Reliability and validity of MRI measurement of the amygdala and hippocampus in children with fragile X syndrome. Psychiatry Res. 75, 31-48. doi: 10.1016/S0925-4927(97)00019-X
108. Keifer, O. P., O'Connor, D. M., and Boulis, N. M. (2014). Gene and protein therapies utilizing VEGF for ALS. Pharmacol. Therap. 141, 261-271. doi: 10.1016/j.pharmthera.2013.10.009
109. Keown, C., Shih, P., Nair, A., Peterson, N., Mulvey, M., and Müller, R. A. (2013). Local functional overconnectivity in posterior brain regions is associated with symptom severity in autism spectrum disorders. Cell Rep. 5, 567-572. doi: 10.1016/j.celrep.2013.10.003
110. Klann, E., and Dever, T. E. (2004). Biochemical mechanisms for translational regulation in synaptic plasticity. Nature Rev. Neurosci. 5, 931-942. doi: 10.1038/nrn1557
111. Kwon, C. H., Luikart, B. W., Powell, C. M., Zhou, J., Matheny, S. A., Zhang, W., et al. (2006). Pten regulates neuronal arborization and social interaction in mice. Neuron 50, 377-388. doi: 10.1016/j.neuron.2006.03.023
112. Kwon, C.-H., Zhu, X., Zhang, J., and Baker, S. J. (2003). mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo. Proc. Natl. Acad. Sci. U.S.A. 100, 12923-12928. doi: 10.1073/pnas.2132711100
113. Kwon, C. H., Zhu, X., Zhang, J., Knoop, L. L., Tharp, R., Smeyne, R. J., et al. (2001). Pten regulates neuronal soma size: a mouse model of Lhermitte-Duclos disease. Nat. Genet. 29, 404-411. doi: 10.1038/ng781
114. Laplante, M., and Sabatini, D. M. (2012). MTOR signaling in growth control and disease. Cell 149, 274-293. doi: 10.1016/j.cell.2012.03.017
115. Laviola, L., Natalicchio, A., and Giorgino, F. (2007). The IGF-I signaling pathway. Curr. Pharm. Des. 13, 663-669. doi: 10.2174/138161207780249146
116. Leigh, M. J. S., Nguyen, D. V., Mu, Y., Winarni, T. I., Schneider, A., Chechi, T., et al. (2013). A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome. J. Dev. Behav. Pediatr. 34, 147-155. doi: 10.1097/DBP.0b013e318287cd17
117. Li, Y., Wang, H., Muffat, J., Cheng, A. W., Orlando, D. A., Lovén, J., and Jaenisch, R. (2013). Global transcriptional and translational repression in human-embryonic-stem-cell-derived Rett syndrome neurons. Cell Stem Cell 13, 446-458. doi: 10.1016/j.stem.2013.09.001
118. Liang, P., Wan, Y., Yan, Y., Wang, Y., Luo, N., Deng, Y., et al. (2010). MVP interacts with YPEL4 and inhibits YPEL4-mediated activities of the ERK signal pathway. Biochem. Cell Biol. 88, 445-450. doi: 10.1139/O09-166
119. Louhivuori, V., Vicario, A., Uutela, M., Rantamäki, T., Louhivuori, L. M., Castrén, E., et al. (2011). BDNF and TrkB in neuronal differentiation of Fmr1-knockout mouse. Neurobiol. Dis. 41, 469-480. doi: 10.1016/j.nbd.2010.10.018
120. Lu, L., Hope, B. T., Dempsey, J., Liu, S. Y., Bossert, J. M., and Shaham, Y. (2005). Central amygdala ERK signaling pathway is critical to incubation of cocaine craving. Nat. Neurosci. 8, 212-219. doi: 10.1038/nn1383
121. Lugtenberg, D., Kleefstra, T., Oudakker, A. R., Nillesen, W. M., Yntema, H. G., Tzschach, A., et al. (2009). Structural variation in Xq28: MECP2 duplications in 1% of patients with unexplained XLMR and in 2% of male patients with severe encephalopathy. Eur. J. Hum. Genet. 17, 444-453. doi: 10.1038/ejhg.2008.208
122. Luikenhuis, S., Giacometti, E., Beard, C. F., and Jaenisch, R. (2004). Expression of MeCP2 in postmitotic neurons rescues Rett syndrome in mice. Proc. Natl. Acad. Sci. U.S.A. 101, 6033-6038. doi: 10.1073/pnas.0401626101
123. Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P., and Pandolfi, P. P. (2005). Phosphorylation and functional inactivation of TSC2 by Erk: implications for tuberous sclerosis and cancer pathogenesis. Cell 121, 179-193. doi: 10.1016/j.cell.2005.02.031
124. Ma, L., Teruya-Feldstein, J., Bonner, P., Bernardi, R., Franz, D. N., Witte, D., et al. (2007). Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase-mediated mTOR activation in tuberous sclerosis and human cancer. Cancer Res. 67, 7106-7112. doi: 10.1158/0008-5472.CAN-06-4798
125. Ma, X. M., and Blenis, J. (2009). Molecular mechanisms of mTOR-mediated translational control. Nat. Rev. Mol. Cell Biol. 10, 307-318. doi: 10.1038/nrm2672
126. Malhotra, D., and Sebat, J. (2012). CNVs: Harbingers of a rare variant revolution in psychiatric genetics. Cell 148, 1223-1241. doi: 10.1016/j.cell.2012.02.039
127. Marshall, C. R., Noor, A., Vincent, J. B., Lionel, A. C., Feuk, L., Skaug, J., et al. (2008). Structural variation of chromosomes in autism spectrum disorder. Am. J. Hum. Genet. 82, 477-488. doi: 10.1016/j.ajhg.2007.12.009
128. Martinowich, K., Hattori, D., Wu, H., Fouse, S., He, F., Hu, Y., et al. (2003). DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. Science 302, 890-893. doi: 10.1126/science.1090842
129. Martinowich, K., Manji, H., and Lu, B. (2007). New insights into BDNF function in depression and anxiety. Nat. Neurosci. 10, 1089-1093. doi: 10.1038/nn1971
130. Marui, T., Hashimoto, O., Nanba, E., Kato, C., Tochigi, M., Umekage, T., et al. (2004). Association between the neurofibromatosis-1 (NF1) locus and autism in the Japanese population. Am. J. Med. Genet. B Neuropsychiatr. Genet. 131B(1), 43-47. doi: 10.1002/ajmg.b.20119
131. Matijevic, T., Knezevic, J., Slavica, M., and Pavelic, J. (2009). Rett syndrome: from the gene to the disease. Eur. Neurol. 61, 3-10. doi: 10.1159/000165342
132. McBride, K. L., Varga, E. A., Pastore, M. T., Prior, T. W., Manickam, K., Atkin, J. F., et al. (2010). Confirmation study of PTEN mutations among individuals with autism or developmental delays/mental retardation and macrocephaly. Autism Res. 3, 137-141. doi: 10.1002/aur.132
133. McCarthy, S. E., Makarov, V., Kirov, G., Addington, A. M., McClellan, J., Yoon, S., et al. (2009). Microduplications of 16p11.2 are associated with schizophrenia. Nat. Genet. 41, 1223-1227. doi: 10.1038/ng.474
134. McGraw, C. M., Samaco, R. C., and Zoghbi, H. Y. (2011). Adult neural function requires MeCP2. Science 333, 186. doi: 10.1126/science.1206593
135. Meikle, L., Talos, D. M., Onda, H., Pollizzi, K., Rotenberg, A., Sahin, M., et al. (2007). A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. J. Neurosci. 27, 5546-5558. doi: 10.1523/JNEUROSCI.5540-06.2007
136. Michalon, A., Sidorov, M., Ballard, T. M., Ozmen, L., Spooren, W., Wettstein, J. G., et al. (2012). Chronic pharmacological mGlu5 inhibition corrects Fragile X in adult mice. Neuron 74, 49-56. doi: 10.1016/j.neuron.2012.03.009
137. Mizoguchi, T., Togawa, S., Kawakami, K., and Itoh, M. (2011). Neuron and sensory epithelial cell fate is sequentially determined by notch signaling in zebrafish lateral line development. J. Neurosci. 31, 15522-15530. doi: 10.1523/JNEUROSCI.3948-11.2011
138. Moreno-De-Luca, D., Mulle, J. G., Kaminsky, E. B., Sanders, S. J., Myers, S. M., Adam, M. P., et al. (2010). Deletion 17q12 is a recurrent copy number variant that confers high risk of autism and schizophrenia. Am. J. Hum. Genet. 87, 618-630. doi: 10.1016/j.ajhg.2010.10.004
139. Mukaddes, N. M., and Herguner, S. (2007). Autistic disorder and 22q11.2 duplication. World J. Biol. Psychiatry 8, 127-130. doi: 10.1080/15622970601026701
140. Mukai, J., Dhilla, A., Drew, L. J., Stark, K. L., Cao, L., MacDermott, A. B., et al. (2008). Palmitoylation-dependent neurodevelopmental deficits in a mouse model of 22q11 microdeletion. Nat. Neurosci. 11, 1302-1310. doi: 10.1038/nn.2204
141. Müller, R. A., Shih, P., Keehn, B., Deyoe, J. R., Leyden, K. M., and Shukla, D. K. (2011). Underconnected, but how? A survey of functional connectivity MRI studies in autism spectrum disorders. Cereb. Cortex 21, 2233-2243. doi: 10.1093/cercor/bhq296
142. Murphy, L. O., and Blenis, J. (2006). MAPK signal specificity: the right place at the right time. Trends Biochem. Sci. 31, 268-275. doi: 10.1016/j.tibs.2006.03.009
143. Nishimura, K., Nakamura, K., Anitha, A., Yamada, K., Tsujii, M., Iwayama, Y., et al. (2007). Genetic analyses of the brain-derived neurotrophic factor (BDNF) gene in autism. Biochem. Biophys. Res. Commun. 356, 200-206. doi: 10.1016/j.bbrc.2007.02.135
144. Nowicki, S. T., Tassone, F., Ono, M. Y., Ferranti, J., Croquette, M. F., Goodlin-Jones, B., et al. (2007). The Prader-Willi phenotype of fragile X syndrome. J. Dev. Behav. Pediatr. 28, 133-138. doi: 10.1097/01.DBP.0000267563.18952.c9
145. O'Roak, B. J., Vives, L., Girirajan, S., Karakoc, E., Krumm, N., Coe, B. P., et al. (2012). Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature 485, 246-250. doi: 10.1038/nature10989
146. Oksenberg, N., and Ahituv, N. (2013). The role of AUTS2 in neurodevelopment and human evolution. Trends Genet. 29, 600-608. doi: 10.1016/j.tig.2013.08.001
147. Ola, M. S., Nawaz, M. I., Khan, H. A., and Alhomida, A. S. (2013). Neurodegeneration and neuroprotection in diabetic retinopathy. Int. J. Mol. Sci. 14, 2559-2572. doi: 10.3390/ijms14022559
148. Osterweil, E. K., Chuang, S. C., Chubykin, A. A., Sidorov, M., Bianchi, R., Wong, R. K. S., et al. (2013). Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of Fragile X syndrome. Neuron 77, 243-250. doi: 10.1016/j.neuron.2012.01.034
149. Ouchi, Y., Banno, Y., Shimizu, Y., Ando, S., Hasegawa, H., Adachi, K., et al. (2013). Reduced adult hippocampal neurogenesis and working memory deficits in the Dgcr8-deficient mouse model of 22q11.2 deletion-associated schizophrenia can be rescued by IGF2. J. Neurosci. 33, 9408-9419. doi: 10.1523/JNEUROSCI.2700-12.2013
150. Pan, F., Aldridge, G. M., Greenough, W. T., and Gan, W.-B. (2010). Dendritic spine instability and insensitivity to modulation by sensory experience in a mouse model of fragile X syndrome. Proc. Natl. Acad. Sci. U.S.A. 107, 17768-17773. doi: 10.1073/pnas.1012496107
151. Paribello, C., Tao, L., Folino, A., Berry-Kravis, E., Tranfaglia, M., Ethell, I. M., et al. (2010). Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol. 10, 91. doi: 10.1186/1471-2377-10-91
152. Park, H., and Poo, M. M. (2013). Neurotrophin regulation of neural circuit development and function. Nat. Rev. Neurosci. 14, 7-23. doi: 10.1038/nrn3379
153. Penagarikano, O., Mulle, J. G., and Warren, S. T. (2007). The pathophysiology of fragile x syndrome. Annu. Rev. Genomics Hum. Genet. 8, 109-129. doi: 10.1146/annurev.genom.8.080706.092249
154. Peprah, E. (2012). Fragile X Syndrome: The FMR1 CGG Repeat Distribution Among World Populations. Ann. Hum. Genet. 76, 178-191. doi: 10.1111/j.1469-1809.2011.00694.x
155. Persico, A. M., and Bourgeron, T. (2006). Searching for ways out of the autism maze: genetic, epigenetic and environmental clues. Trends Neurosci. 29, 349-358. doi: 10.1016/j.tins.2006.05.010
156. Pinto, D., Pagnamenta, A. T., Klei, L., Anney, R., Merico, D., Regan, R., et al. (2010). Functional impact of global rare copy number variation in autism spectrum disorders. Nature 466, 368-372. doi: 10.1038/nature09146
157. Poo, M. M. (2001). Neurotrophins as synaptic modulators. Nat. Rev. Neurosci. 2, 24-32. doi: 10.1038/35049004
158. Portmann, T., Yang, M., Mao, R., Panagiotakos, G., Ellegood, J., Dolen, G., et al. (2014). Behavioral abnormalities and circuit defects in the basal ganglia of a mouse model of 16p11.2 deletion syndrome. Cell Rep. 7, 1077-1092. doi: 10.1016/j.celrep.2014.03.036
159. Pucilowska, J., Vithayathil, J., Tavares, E. J., Kelly, C., Karlo, J. C., and Landreth, G. E. (2015). The 16p11.2 deletion mouse model of autism exhibits altered cortical progenitor proliferation and brain cytoarchitecture linked to the ERK MAPK pathway. J. Neurosci. 35, 3190-3200. doi: 10.1523/JNEUROSCI.4864-13.2015
160. Qureshi, A. Y., Mueller, S., Snyder, A. Z., Mukherjee, P., Berman, J. I., Roberts, T. P. L., et al. (2014). Opposing brain differences in 16p11.2 deletion and duplication carriers. J. Neurosci. 34, 11199-11211. doi: 10.1523/JNEUROSCI.1366-14.2014
161. Ramocki, M. B., Tavyev, Y. J., and Peters, S. U. (2010). The MECP2 duplication syndrome. Am. J. Med. Genet. A. 152A, 1079-1088. doi: 10.1002/ajmg.a.33184
162. Reichardt, L. F. (2006). Neurotrophin-regulated signalling pathways. Philos. Trans. R. Soc. Lond. B Biol. Sci. 361, 1545-1564. doi: 10.1098/rstb.2006.1894
163. Reiss, A. L., Faruque, F., Naidu, S., Abrams, M., Beaty, T., Bryan, R. N., et al. (1993). Neuroanatomy of Rett syndrome: a volumetric imaging study. Ann. Neurol. 34, 227-234. doi: 10.1002/ana.410340220
164. Ricceri, L., De Filippis, B., and Laviola, G. (2008). Mouse models of Rett syndrome: from behavioural phenotyping to preclinical evaluation of new therapeutic approaches. Behav. Pharmacol. 19, 501-517. doi: 10.1097/FBP.0b013e32830c3645
165. Ronemus, M., Iossifov, I., Levy, D., and Wigler, M. (2014). The role of de novo mutations in the genetics of autism spectrum disorders. Nat. Rev. Genet. 15, 133-141. doi: 10.1038/nrg3585
166. Sadakata, T., and Furuichi, T. (2009). Developmentally regulated Ca2+-dependent activator protein for secretion 2 (CAPS2) is involved in BDNF secretion and is associated with autism susceptibility. Cerebellum 8, 312-322. doi: 10.1007/s12311-009-0097-5
167. Samuels, I. S., Karlo, J. C., Faruzzi, A. N., Pickering, K., Herrup, K., Sweatt, J. D., et al. (2008). Deletion of ERK2 mitogen-activated protein kinase identifies its key roles in cortical neurogenesis and cognitive function. J. Neurosci. 28, 6983-6995. doi: 10.1523/JNEUROSCI.0679-08.2008
168. Samuels, I. S., Saitta, S. C., and Landreth, G. E. (2009). MAP'ing CNS development and cognition: an ERKsome process. Neuron 61, 160-167. doi: 10.1016/j.neuron.2009.01.001
169. Santini, E., Huynh, T. N., MacAskill, A. F., Carter, A. G., Pierre, P., Ruggero, D., et al. (2013). Exaggerated translation causes synaptic and behavioural aberrations associated with autism. Nature 493, 411-415. doi: 10.1038/nature11782
170. Sato, A., Kasai, S., Kobayashi, T., Takamatsu, Y., Hino, O., Ikeda, K., et al. (2012). Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex. Nat. Commun. 3, 1292. doi: 10.1038/ncomms2295
171. Satoh, Y., Kobayashi, Y., Takeuchi, A., Pagès, G., Pouysségur, J., and Kazama, T. (2011). Deletion of ERK1 and ERK2 in the CNS causes cortical abnormalities and neonatal lethality: Erk1 deficiency enhances the impairment of neurogenesis in Erk2-deficient mice. J. Neurosci. 31, 1149-1155. doi: 10.1523/JNEUROSCI.2243-10.2011
172. Schofield, C. M., Hsu, R., Barker, A. J., Gertz, C. C., Blelloch, R., and Ullian, E. M. (2011). Monoallelic deletion of the microRNA biogenesis gene Dgcr8 produces deficits in the development of excitatory synaptic transmission in the prefrontal cortex. Neural Dev. 6:11. doi: 10.1186/1749-8104-6-11
173. Schüle, B., Armstrong, D. D., Vogel, H., Oviedo, A., and Francke, U. (2008). Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure. Clin. Genet. 74, 116-126. doi: 10.1111/j.1399-0004.2008.01005.x
174. Sharma, A., Hoeffer, C. A., Takayasu, Y., Miyawaki, T., McBride, S. M., Klann, E., et al. (2010). Dysregulation of mTOR signaling in fragile X syndrome. J. Neurosci. 30, 694-702. doi: 10.1523/JNEUROSCI.3696-09.2010
175. Shi, D., Xu, S., Waddell, J., Scafidi, S., Roys, S., Gullapalli, R. P., et al. (2012). Longitudinal in vivo developmental changes of metabolites in the hippocampus of Fmr1 knockout mice. J. Neurochem. 123, 971-981. doi: 10.1111/jnc.12048
176. Shinawi, M., Liu, P., Kang, S.-H. L., Shen, J., Belmont, J. W., Scott, D. A., et al. (2010). Recurrent reciprocal 16p11.2 rearrangements associated with global developmental delay, behavioural problems, dysmorphism, epilepsy, and abnormal head size. J. Med. Genet. 47, 332-341. doi: 10.1136/jmg.2009.073015
177. Shiota, C., Woo, J. T., Lindner, J., Shelton, K. D., and Magnuson, M. A. (2006). Multiallelic disruption of the rictor gene in mice reveals that mTOR Complex 2 is essential for fetal growth and viability. Dev. Cell 11, 583-589. doi: 10.1016/j.devcel.2006.08.013
178. Sidhu, H., Dansie, L. E., Hickmott, P. W., Ethell, D. W., and Ethell, I. M. (2014). Genetic removal of matrix metalloproteinase 9 rescues the symptoms of fragile X syndrome in a mouse model. J. Neurosci. 34, 9867-9879. doi: 10.1523/JNEUROSCI.1162-14.2014
179. Sigurdsson, T., Stark, K. L., Karayiorgou, M., Gogos, J. A., and Gordon, J. A. (2010). Impaired hippocampal-prefrontal synchrony in a genetic mouse model of schizophrenia. Nature 464, 763-767. doi: 10.1038/nature08855
180. Slegtenhorst-Eegdeman, K. E., de Rooij, D. G., Verhoef-Post, M., van de Kant, H. J., Bakker, C. E., Oostra, B. A., et al. (1998). Macroorchidism in FMR1 knockout mice is caused by increased Sertoli cell proliferation during testicular development. Endocrinology 139, 156-162. doi: 10.1210/en.139.1.156
181. Spence, S. J., Cantor, R. M., Chung, L., Kim, S., Geschwind, D. H., and Alarcón, M. (2006). Stratification based on language-related endophenotypes in autism: attempt to replicate reported linkage. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141, 591-598. doi: 10.1002/ajmg.b.30329
182. Sultana, R., Yu, C.-E., Yu, J., Munson, J., Chen, D., Hua, W., et al. (2002). Identification of a novel gene on chromosome 7q11.2 interrupted by a translocation breakpoint in a pair of autistic twins. Genomics 80, 129-134. doi: 10.1006/geno.2002.6810
183. Supekar, K., Uddin, L. Q., Khouzam, A., Phillips, J., Gaillard, W. D., Kenworthy, L. E., et al. (2013). Brain Hyperconnectivity in Children with Autism and its Links to Social Deficits. Cell Rep. 5, 738-747. doi: 10.1016/j.celrep.2013.10.001
184. Sweatt, J. D. (2004). Mitogen-activated protein kinases in synaptic plasticity and memory. Curr. Opin. Neurobiol. 14, 311-317. doi: 10.1016/j.conb.2004.04.001
185. Takei, N., and Nawa, H. (2014). mTOR signaling and its roles in normal and abnormal brain development. Front. Mol. Neurosci. 7:28. doi: 10.3389/fnmol.2014.00028
186. Tang, G., Gudsnuk, K., Kuo, S. H., Cotrina, M. L., Rosoklija, G., Sosunov, A., et al. (2014). Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits. Neuron 83, 1131-1143. doi: 10.1016/j.neuron.2014.07.040
187. Thomanetz, V., Angliker, N., Cloëtta, D., Lustenberger, R. M., Schweighauser, M., Oliveri, F., et al. (2013). Ablation of the mTORC2 component rictor in brain or Purkinje cells affects size and neuron morphology. J. Cell Biol. 201, 293-308. doi: 10.1083/jcb.201205030
188. Tian, D., Stoppel, L. J., Heynen, A. J., Lindemann, L., Jaeschke, G., Mills, A. A., et al. (2015). Contribution of mGluR5 to pathophysiology in a mouse model of human chromosome 16p11.2 microdeletion. Nat. Neurosci. 18, 182-184. doi: 10.1038/nn.3911
189. Tsai, S. J. (2005). Is autism caused by early hyperactivity of brain-derived neurotrophic factor? Med. Hypotheses 65, 79-82. doi: 10.1016/j.mehy.2005.01.034
190. Uutela, M., Lindholm, J., Louhivuori, V., Wei, H., Louhivuori, L. M., Pertovaara, A., et al. (2012). Reduction of BDNF expression in Fmr1 knockout mice worsens cognitive deficits but improves hyperactivity and sensorimotor deficits. Genes Brain Behav. 11, 513-523. doi: 10.1111/j.1601-183X.2012.00784.x
191. Van Bon, B. W. M., Coe, B. P., Bernier, R., Green, C., Gerdts, J., Witherspoon, K., et al. (2015). Disruptive de novo mutations of DYRK1A lead to a syndromic form of autism and ID. Mol. Psychiatry. doi: 10.1038/mp.2015.5. [Epub ahead of print]
192. Varga, E. A., Pastore, M., Prior, T., Herman, G. E., and McBride, K. L. (2009). The prevalence of PTEN mutations in a clinical pediatric cohort with autism spectrum disorders, developmental delay, and macrocephaly. Genet. Med. 11, 111-117. doi: 10.1097/GIM.0b013e31818fd762
193. Vissers, M. E., Cohen, M. X., and Geurts, H. M. (2012). Brain connectivity and high functioning autism: a promising path of research that needs refined models, methodological convergence, and stronger behavioral links. Neurosci. Biobehav. Rev. 36, 604-625. doi: 10.1016/j.neubiorev.2011.09.003
194. Walters, R. G., Jacquemont, S., Valsesia, A., de Smith, A. J., Martinet, D., Andersson, J., et al. (2010). A new highly penetrant form of obesity due to deletions on chromosome 16p11.2. Nature 463, 671-675. doi: 10.1038/nature08727
195. Wang, X., Snape, M., Klann, E., Stone, J. G., Singh, A., Petersen, R. B., et al. (2012). Activation of the extracellular signal-regulated kinase pathway contributes to the behavioral deficit of fragile x-syndrome. J. Neurochem. 121, 672-679. doi: 10.1111/j.1471-4159.2012.07722.x
196. Weiss, L. A., Shen, Y., Korn, J. M., Arking, D. E., Miller, D. T., Fossdal, R., et al. (2008). Association between microdeletion and microduplication at 16p11.2 and autism. N. Engl. J. Med. 358, 667-675. doi: 10.1056/NEJMoa075974
197. Weissmiller, A. M., and Wu, C. (2012). Current advances in using neurotrophic factors to treat neurodegenerative disorders. Transl. Neurodegener. 1:14. doi: 10.1186/2047-9158-1-14
198. Worby, C. A., and Dixon, J. E. (2014). PTEN. Annu. Rev. Biochem. 83, 641-669. doi: 10.1146/annurev-biochem-082411-113907
199. Wu, G. Y., Deisseroth, K., and Tsien, R. W. (2001). Spaced stimuli stabilize MAPK pathway activation and its effects on dendritic morphology. Nat. Neurosci. 4, 151-158. doi: 10.1038/83976
200. Xu, B., Karayiorgou, M., and Gogos, J. A. (2010). MicroRNAs in psychiatric and neurodevelopmental disorders. Brain Res. 1338, 78-88. doi: 10.1016/j.brainres.2010.03.109
201. Yagi, H., Furutani, Y., Hamada, H., Sasaki, T., Asakawa, S., Minoshima, S., et al. (2003). Role of TBX1 in human del22q11.2 syndrome. Lancet 362, 1366-1373. doi: 10.1016/S0140-6736(03)14632-6
202. Yuan, T. L., and Cantley, L. C. (2008). PI3K pathway alterations in cancer: variations on a theme. Oncogene 27, 5497-5510. doi: 10.1038/onc.2008.245
203. Yufune, S., Satoh, Y., Takamatsu, I., Ohta, H., Kobayashi, Y., Takaenoki, Y., et al. (2015). Transient blockade of ERK phosphorylation in the critical period causes autistic phenotypes as an adult in mice. Sci. Rep. 5:10252. doi: 10.1038/srep10252
204. Zhang, H., Cicchetti, G., Onda, H., Koon, H. B., Asrican, K., Bajraszewski, N., et al. (2003). Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J. Clin. Invest. 112, 1223-1233. doi: 10.1172/JCI200317222
205. Zhou, J., Blundell, J., Ogawa, S., Kwon, C.-H., Zhang, W., Sinton, C., et al. (2009). Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice. J. Neurosci. 29, 1773-1783. doi: 10.1523/JNEUROSCI.5685-08.2009
206. Zhou, J., and Parada, L. F. (2012). PTEN signaling in autism spectrum disorders. Curr. Opin. Neurobiol. 22, 873-879. doi: 10.1016/j.conb.2012.05.004
207. Zhou, Z., Hong, E. J., Cohen, S., Zhao, W., Ho, H. Y., Schmidt, L., et al. (2006). Brain-specific phosphorylation of MeCP2 regulates activity-dependent Bdnf transcription, dendritic growth, and spine maturation. Neuron 52, 255-269. doi: 10.1016/j.neuron.2006.09.037
208. Zoghbi, H. Y., and Bear, M. F. (2012). Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities. Cold Spring Harb. Perspect. Biol. 4:a009886. doi: 10.1101/cshperspect.a009886
209. Zoncu, R., Efeyan, A., and Sabatini, D. M. (2011). mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 12, 21-35. doi: 10.1038/nrm3025
210. Zuccato, C., and Cattaneo, E. (2009). Brain-derived neurotrophic factor in neurodegenerative diseases. Nat. Rev. Neurol. 5, 311-322. doi: 10.1038/nrneurol.2009.54
211. Zufferey, F., Sherr, E. H., Beckmann, N. D., Hanson, E., Maillard, A. M., Hippolyte, L., et al. (2012). A 600 kb deletion syndrome at 16p11.2 leads to energy imbalance and neuropsychiatric disorders. J. Med. Genet. 49, 660-668. doi: 10.1136/jmedgenet-2012-101203